Pharmacotherapy For Hematologic
Disorders HW 6
Pharmacotherapy For Hematologic Disorders HW 6
In the 1970s, the average lifespan for patients diagnosed with
sickle cell disease was 14 years. Today, the average lifespan has
increased to 50 years and beyond (TriHealth, 2012). The patient
prognosis for many other hematologic disorders such as
hemophilia and cancer continue to improve as well. This can be
attributed to advancements in medical care—specifically drug
therapy and treatment. When managing drug therapies for
patients, it is essential to continuously examine current treatments
and evaluate the impact of patient factors on drug effectiveness.
To prepare for your role as an advanced practice nurse, you must
become familiar with common drug treatments for various
hematologic disorders seen in clinical settings.
Select one of the following hematologic disorders: anemia,
hemophilia, cancer, sickle cell anemia, thalassemia, thrombolytic
disorders, or white blood cell disorders. Consider the types of
drugs that would be prescribed to patients to treat symptoms
associated with this disorder.
Select one of the following factors: genetics, gender, ethnicity,
age, or behavior. Reflect on how this factor might impact the
effects of prescribed drugs, as well as any measures you might